Bota Bio and Agilent deepened strategic partnership
- Joint efforts to develop solutions for synthetic biology manufacturing, research, development and application.
Bota Bio and Agilent recently signed a strategic cooperation agreement aimed at further strengthening multi-form and multi-level resource sharing and technical exchanges. Both parties will explore the development and application of emerging technologies for the synthetic biology field.
Bota Bio has been working closely with Agilent since 2019. Bota Bio’s analytical platform is equipped with a variety of high-end equipment from Agilent, including ultra-high-performance liquid chromatography (UHPLC), gas chromatography (GC), liquid chromatography with tandem mass spectrometry (LC-MS/MS), gas chromatography-mass spectrometer (GC-MS) and RapidFire high-throughput liquid mass spectrometry system. These tools have significantly improved the speed and precision of sample analysis, proving essential for high-throughput screening and process optimization at Bota Bio.
After deepening strategic cooperation, Bota Bio and Agilent will share the advantages of innovative technology and industrial resources to optimize the application of metabolic flow analysis, protein quantification, fermentation online detection, and other applications in the field of synthetic biology. The comprehensive real-time data will alleviate the bottleneck of research and development and it will satisfy the analytical needs for each key step in the process of industrialization.
Ting Yang, the Vice President and General Manager of Agilent’s Greater China, said, “We are delighted to have reached in-depth strategic cooperation with Bota Bio, the world’s leading biotechnology company. Many of Agilent’s technologies support the research and industrial development of synthetic biology and facilitate the DBTL (Design-Build-Test-Learn) cycle. We hope that Agilent’s upcoming groundbreaking technology can be functionally validated and debugged in Bota Bio’s experimental scenarios before going to market, and I believe that the strategic cooperation between us relying on our respective technological advantages will definitely facilitate the development of new technologies and accelerate the progress of the synthetic biology.”
Chia-Hong Tsai, Chief Technology Officer of Bota Bio, said, “Due to technical thresholds that are difficult to overcome in the scientific innovation, it is difficult for us to have a systematic understanding of the entire biological reaction process. Agilent Technology is a global leader in laboratory equipment, reagents, and software. Bota Bio is very honored and convinced that through such strategic cooperation, the most cutting-edge analysis technology can be applied in a practical way, so that online analysis can cover from the R&D to the manufacturing, accelerating the commercilization of synthetic biology.”
About Agilent:
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, committed to providing insights and innovative experience to improve people’s quality of life. Agilent’s instruments, software, services, solutions, and experts provide more reliable solutions to our customers’ most challenging problems. In fiscal year 2022, Agilent’s operating revenue was US$6.85 billion, with 18,000 employees worldwide.
关于Bota Bio（恩和生物）：
Bota Bio is the global biotech company connecting biological design to scale-up biomanufacturing to accelerate the shifts to sustainable living. Bota Bio is led by an experienced, multidisciplinary team of industry veterans delivering on nature’s possibilities to inspire and enable a global transformation with biology. For more information, visit www.bota.bio.